LBT-3627 Parkinson's disease program
phase 1drug program · high · Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate LBT-3627 as a VIPR2 agonist therapeutic intended to restore regulatory T cell activity, reduce neuroinflammation, and protect dopaminergic neurons in Parkinson's disease.
Phase I a/b single- and multiple-ascending-dose clinical trial in healthy participants and participants with Parkinson's disease; preclinical VIPR2 agonist studies in Parkinson's disease models.
Phase I a/b SAD/MAD safety, tolerability, pharmacokinetic, and pharmacodynamic trial registered for healthy participants and Parkinson's disease participants.
Preclinical studies reported increased Treg activity, reduced inflammatory microglia or astrogliosis, dopaminergic neuron sparing, and improved striatal densities in Parkinson's disease models.
Parkinson's disease inflammatory biomarker profiling
exploratorybiomarker · high · Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Identify immunological biomarkers correlated with Parkinson's disease diagnosis and stratify patients by disease severity.
Clinical biomarker profiling study comparing a comprehensive panel of immunological biomarkers between Parkinson's disease patients and healthy environmentally matched participants.
ClinicalTrials.gov record for Parkinson's Disease Inflammatory Biomarker Profiling published.
MEMRI monitoring of VIPR2 agonist therapy response
preclinicalbiomarker · medium · Fri Jan 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop manganese-enhanced MRI as a noninvasive biomarker tool to monitor disease progression and therapeutic efficacy for VIPR2 agonist neuroprotective treatment in Parkinson's disease models.
Manganese-enhanced magnetic resonance imaging assays tracking glial activation and LBT-3627-induced neuroprotective immunity in MPTP-induced nigrostriatal degeneration.
Preclinical publication reported MEMRI signal changes paralleling reduced astrogliosis and dopaminergic neuron sparing after LBT-3627 treatment.
LBT-3627-treated MPTP-intoxicated mice showed reduced MEMRI brain signal intensities, reduced astrogliosis, and sparing of nigral tyrosine hydroxylase neurons.
Hybridtide Platform
undisclosedplatform · medium
Develop precision peptide-based approaches for neurodegenerative disease programs.
Company-described Hybridtide platform and related highly active polypeptide intellectual property for making and using polypeptide analogs.
Platform highlighted on company site alongside the pipeline; related polypeptide patent publications assigned to Longevity Biotech.
